{"gene":"MITD1","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2012,"finding":"MITD1 MIT domain directly interacts with ESCRT-III subunits CHMP1B, CHMP2A, and IST1, and these interactions are required for MITD1 recruitment to the midbody during cytokinesis.","method":"Co-IP/pulldown binding assays and fluorescence microscopy of midbody localization","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding assays plus localization experiments, independently replicated in two concurrent papers (PMID:23015756 and PMID:23045692)","pmids":["23015756","23045692"],"is_preprint":false},{"year":2012,"finding":"MITD1 participates in the abscission phase of cytokinesis; depletion causes midbody destabilization and abscission failure.","method":"siRNA knockdown with cytokinesis phenotype readout (midbody imaging, abscission assay)","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function with defined cellular phenotype, independently reproduced in two concurrent papers (PMID:23015756 and PMID:23045692)","pmids":["23015756","23045692"],"is_preprint":false},{"year":2012,"finding":"MITD1 dimerizes through its C-terminal domain (identified as a phospholipase D-like domain by crystal structure), and this dimerization is important for MITD1 function.","method":"X-ray crystallography of MITD1 revealing a PLD-like dimer, corroborated by biochemical dimerization assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with biochemical validation in one rigorous study; dimerization through C-terminal domain also noted in the parallel paper","pmids":["23045692","23015756"],"is_preprint":false},{"year":2012,"finding":"The C-terminal PLD-like domain of MITD1 binds membranes, as revealed by the crystal structure and membrane-binding assays.","method":"Crystal structure determination plus membrane-binding assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure plus direct membrane-binding assay in a single rigorous paper","pmids":["23045692"],"is_preprint":false},{"year":2012,"finding":"MITD1 negatively regulates the interaction between IST1 and VPS4; because IST1 binding modulates VPS4 ATPase activity, MITD1 may function through downstream effects on VPS4-mediated ESCRT filament remodeling during abscission.","method":"Binding competition assays (Co-IP/pulldown) showing MITD1 reduces IST1-VPS4 interaction","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — defined competitive binding experiment in a single lab, single method for the VPS4-regulation part","pmids":["23015756"],"is_preprint":false},{"year":2023,"finding":"ANKRD35 destabilizes MITD1 protein by binding SUMO2, and RBCK1 (an E3 ubiquitin ligase) promotes ANKRD35 degradation, thereby stabilizing MITD1; the RBCK1-ANKRD35-MITD1-ANXA1 axis regulates AKT and ERK phosphorylation in ccRCC cells.","method":"In vitro and in vivo studies including knockdown/overexpression with signaling readouts (AKT/ERK phosphorylation), protein interaction assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — mechanistic pathway placement with signaling readouts, single lab, multiple methods but not fully reconstituted","pmids":["36732658"],"is_preprint":false},{"year":2022,"finding":"MITD1 knockdown in ccRCC cells induces ferroptosis and suppresses tumor growth and migration through the TAZ/SLC7A11 pathway; TAZ overexpression rescues the ferroptotic phenotype caused by MITD1 loss.","method":"siRNA knockdown with ferroptosis assays, TAZ overexpression rescue experiments, Western blot for SLC7A11","journal":"Oxidative medicine and cellular longevity","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — epistasis (rescue experiment) plus defined pathway placement, single lab","pmids":["36046690"],"is_preprint":false},{"year":2025,"finding":"MITD1 inhibits flavivirus (WNV, USUV, Zika, dengue) RNA replication by sequestering specific ESCRT-III proteins required for the formation of viral replication factories; MITD1 is an interferon-stimulated gene selectively induced in brain cells (microglia) and is an essential mediator of IFN-I anti-flavivirus activity in human microglial-like cells.","method":"Arrayed ISG expression screen, viral replication assays, ESCRT-III interaction studies, IFN-I treatment of microglial-like cells with MITD1 knockdown","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional screen followed by mechanistic validation (ESCRT-III sequestration, cell-type-specific IFN pathway), single lab with multiple orthogonal methods","pmids":["40112111"],"is_preprint":false},{"year":2026,"finding":"FOXO4 binds the MITD1 promoter (identified by ChIP-seq) and transcriptionally upregulates MITD1; MITD1 acts downstream of FOXO4 to protect trophoblast cells from ferroptosis (lipid peroxidation), and FOXO4 knockdown reduces MITD1 levels while overexpression restores them.","method":"ChIP-seq for FOXO4 promoter binding, gain- and loss-of-function experiments with ferroptosis readouts (lipid peroxidation, cell viability)","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP-seq plus functional rescue, single lab, mechanistic link established but not fully reconstituted","pmids":["42201761"],"is_preprint":false}],"current_model":"MITD1 is an ESCRT-III–interacting protein (binding CHMP1B, CHMP2A, and IST1 via its MIT domain) that is recruited to the midbody to facilitate abscission during cytokinesis; its C-terminal phospholipase D-like domain mediates membrane binding and homodimerization, and it negatively regulates IST1–VPS4 interaction to modulate ESCRT filament remodeling. Beyond cytokinesis, MITD1 sequesters ESCRT-III subunits to block flavivirus replication-factory formation as a brain-enriched interferon-stimulated antiviral factor, is transcriptionally controlled by FOXO4 to suppress ferroptosis in trophoblasts via the TAZ/SLC7A11 axis, and is stabilized by the RBCK1–ANKRD35–SUMO2 ubiquitin pathway to regulate AKT/ERK signaling in renal carcinoma cells."},"narrative":{"mechanistic_narrative":"MITD1 is an ESCRT-III–interacting protein that functions in the abscission phase of cytokinesis, where its N-terminal MIT domain directly binds the ESCRT-III subunits CHMP1B, CHMP2A, and IST1 to drive recruitment to the midbody [PMID:23015756, PMID:23045692], and its loss destabilizes the midbody and causes abscission failure [PMID:23015756, PMID:23045692]. Its C-terminal phospholipase D-like domain mediates both homodimerization and direct membrane binding, properties resolved by crystallography that are important for MITD1 function [PMID:23045692, PMID:23015756]. Mechanistically, MITD1 negatively regulates the IST1–VPS4 interaction, positioning it as a modulator of VPS4-driven ESCRT filament remodeling during abscission [PMID:23015756]. Beyond cytokinesis, MITD1 is an interferon-stimulated gene selectively induced in microglia that restricts flavivirus replication by sequestering ESCRT-III subunits required for viral replication-factory formation, and is essential for type I interferon anti-flavivirus activity in human microglial-like cells [PMID:40112111]. In renal carcinoma cells, MITD1 is stabilized through an RBCK1–ANKRD35–SUMO2 ubiquitin axis and influences AKT and ERK phosphorylation [PMID:36732658], while its depletion induces ferroptosis via the TAZ/SLC7A11 pathway [PMID:36046690]; in trophoblasts MITD1 is a transcriptional target of FOXO4 that protects against ferroptotic lipid peroxidation [PMID:42201761].","teleology":[{"year":2012,"claim":"Established that MITD1 is a bona fide ESCRT-III interactor recruited to the midbody, answering how an uncharacterized MIT-domain protein engages the cytokinetic machinery.","evidence":"Reciprocal Co-IP/pulldown binding assays with CHMP1B, CHMP2A, IST1 plus midbody localization microscopy, replicated in two concurrent papers","pmids":["23015756","23045692"],"confidence":"High","gaps":["Relative affinity and stoichiometry of the three ESCRT-III interactions not resolved","Structural basis of MIT-domain recognition not defined here"]},{"year":2012,"claim":"Demonstrated a functional cytokinesis role by showing depletion causes abscission failure, moving MITD1 from a binding partner to a required effector.","evidence":"siRNA knockdown with midbody imaging and abscission phenotype readout, reproduced in two papers","pmids":["23015756","23045692"],"confidence":"High","gaps":["Precise step within abscission that MITD1 controls not pinpointed","Whether the phenotype depends on membrane binding vs ESCRT recruitment not separated"]},{"year":2012,"claim":"Defined the C-terminal domain architecture, revealing a PLD-like fold that mediates dimerization and membrane binding, explaining how MITD1 couples to membranes.","evidence":"X-ray crystallography of the MITD1 PLD-like dimer plus biochemical dimerization and membrane-binding assays","pmids":["23045692","23015756"],"confidence":"High","gaps":["Lipid specificity of membrane binding not characterized","Whether the PLD-like domain retains catalytic activity not addressed"]},{"year":2012,"claim":"Proposed a regulatory mechanism in which MITD1 tunes ESCRT remodeling by antagonizing the IST1–VPS4 interaction.","evidence":"Binding competition Co-IP/pulldown assays showing MITD1 reduces IST1-VPS4 interaction","pmids":["23015756"],"confidence":"Medium","gaps":["Single method/single lab for the VPS4-regulation claim","Direct consequence on VPS4 ATPase activity in cells not measured"]},{"year":2022,"claim":"Linked MITD1 to ferroptosis control in cancer, showing its loss triggers ferroptotic death via a defined signaling axis.","evidence":"siRNA knockdown with ferroptosis assays and TAZ-overexpression rescue, SLC7A11 Western blot in ccRCC cells","pmids":["36046690"],"confidence":"Medium","gaps":["Single lab","How a cytokinetic ESCRT protein mechanistically connects to TAZ/SLC7A11 not resolved"]},{"year":2023,"claim":"Placed MITD1 within a ubiquitin/SUMO stabilization network governing its protein levels and downstream AKT/ERK signaling in renal carcinoma.","evidence":"Knockdown/overexpression with AKT/ERK phosphorylation readouts and protein interaction assays in ccRCC, in vitro and in vivo","pmids":["36732658"],"confidence":"Medium","gaps":["Pathway not fully reconstituted in vitro","Direct mechanism linking MITD1-ANXA1 to AKT/ERK not detailed"]},{"year":2025,"claim":"Revealed an antiviral role, establishing MITD1 as a brain-enriched interferon-stimulated gene that blocks flavivirus replication by sequestering ESCRT-III.","evidence":"Arrayed ISG screen, viral replication assays, ESCRT-III interaction studies, and IFN-I treatment with MITD1 knockdown in microglial-like cells","pmids":["40112111"],"confidence":"Medium","gaps":["Single lab","Which specific ESCRT-III subunits are rate-limiting for sequestration not fully defined","In vivo relevance of microglial restriction not established"]},{"year":2026,"claim":"Identified upstream transcriptional control of MITD1 by FOXO4 in a ferroptosis-protective context in trophoblasts.","evidence":"FOXO4 ChIP-seq promoter binding plus gain/loss-of-function with lipid peroxidation and viability readouts","pmids":["42201761"],"confidence":"Medium","gaps":["Single lab and not fully reconstituted","Molecular mechanism by which MITD1 suppresses lipid peroxidation not defined"]},{"year":null,"claim":"How the conserved ESCRT-III/membrane-binding biochemistry of MITD1 mechanistically connects to its disparate ferroptosis, signaling, and antiviral roles remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying mechanism linking cytokinetic ESCRT function to ferroptosis/AKT-ERK regulation","Cell-type specificity of the antiviral vs proliferative roles not reconciled"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[3]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,4]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[7]}],"localization":[{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7]}],"complexes":[],"partners":["CHMP1B","CHMP2A","IST1","VPS4","ANKRD35","RBCK1","FOXO4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8WV92","full_name":"MIT domain-containing protein 1","aliases":[],"length_aa":249,"mass_kda":29.3,"function":"Required for efficient abscission at the end of cytokinesis, together with components of the ESCRT-III complex","subcellular_location":"Late endosome membrane; Midbody; Membrane","url":"https://www.uniprot.org/uniprotkb/Q8WV92/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MITD1","classification":"Not Classified","n_dependent_lines":14,"n_total_lines":1208,"dependency_fraction":0.011589403973509934},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CALM2","stoichiometry":0.2},{"gene":"CLTA","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/MITD1","total_profiled":1310},"omim":[{"mim_id":"621505","title":"ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 35; ANKRD35","url":"https://www.omim.org/entry/621505"},{"mim_id":"621486","title":"MICROTUBULE-INTERACTING AND TRAFFICKING DOMAIN-CONTAINING PROTEIN 1; MITD1","url":"https://www.omim.org/entry/621486"},{"mim_id":"610924","title":"RANBP-TYPE AND C3HC4-TYPE ZINC FINGER-CONTAINING 1; RBCK1","url":"https://www.omim.org/entry/610924"},{"mim_id":"610893","title":"CHARGED MULTIVESICULAR BODY PROTEIN 2A; CHMP2A","url":"https://www.omim.org/entry/610893"},{"mim_id":"151690","title":"ANNEXIN A1; ANXA1","url":"https://www.omim.org/entry/151690"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Vesicles","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MITD1"},"hgnc":{"alias_symbol":["LOC129531"],"prev_symbol":[]},"alphafold":{"accession":"Q8WV92","domains":[{"cath_id":"1.20.58.80","chopping":"10-84","consensus_level":"high","plddt":92.7925,"start":10,"end":84},{"cath_id":"3.30.870.30","chopping":"89-241","consensus_level":"high","plddt":95.4933,"start":89,"end":241}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WV92","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WV92-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WV92-F1-predicted_aligned_error_v6.png","plddt_mean":91.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MITD1","jax_strain_url":"https://www.jax.org/strain/search?query=MITD1"},"sequence":{"accession":"Q8WV92","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8WV92.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8WV92/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WV92"}},"corpus_meta":[{"pmid":"23015756","id":"PMC_23015756","title":"MITD1 is recruited to midbodies by ESCRT-III and participates in cytokinesis.","date":"2012","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/23015756","citation_count":37,"is_preprint":false},{"pmid":"23045692","id":"PMC_23045692","title":"ESCRT-III binding protein MITD1 is involved in cytokinesis and has an unanticipated PLD fold that binds membranes.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23045692","citation_count":30,"is_preprint":false},{"pmid":"36046690","id":"PMC_36046690","title":"MITD1 Deficiency Suppresses Clear Cell Renal Cell Carcinoma Growth and Migration by Inducing Ferroptosis through the TAZ/SLC7A11 Pathway.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/36046690","citation_count":20,"is_preprint":false},{"pmid":"36732658","id":"PMC_36732658","title":"The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis.","date":"2023","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/36732658","citation_count":11,"is_preprint":false},{"pmid":"35293026","id":"PMC_35293026","title":"LncRNA SLC16A1-AS1 contributes to the progression of hepatocellular carcinoma cells by modulating miR-411/MITD1 axis.","date":"2022","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/35293026","citation_count":9,"is_preprint":false},{"pmid":"40112111","id":"PMC_40112111","title":"MITD1 is a brain-specific interferon-inducible factor that inhibits flavivirus replication.","date":"2025","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/40112111","citation_count":4,"is_preprint":false},{"pmid":"42201761","id":"PMC_42201761","title":"Transcriptional Control by FOXO4 Regulates Trophoblast Differentiation and Safeguards Placental Development Through MITD1- and PCBP2-Mediated Redox Homeostasis.","date":"2026","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/42201761","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":5650,"output_tokens":2159,"usd":0.024667,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9131,"output_tokens":2841,"usd":0.05834,"stage2_stop_reason":"end_turn"},"total_usd":0.083007,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2012,\n      \"finding\": \"MITD1 MIT domain directly interacts with ESCRT-III subunits CHMP1B, CHMP2A, and IST1, and these interactions are required for MITD1 recruitment to the midbody during cytokinesis.\",\n      \"method\": \"Co-IP/pulldown binding assays and fluorescence microscopy of midbody localization\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding assays plus localization experiments, independently replicated in two concurrent papers (PMID:23015756 and PMID:23045692)\",\n      \"pmids\": [\"23015756\", \"23045692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MITD1 participates in the abscission phase of cytokinesis; depletion causes midbody destabilization and abscission failure.\",\n      \"method\": \"siRNA knockdown with cytokinesis phenotype readout (midbody imaging, abscission assay)\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function with defined cellular phenotype, independently reproduced in two concurrent papers (PMID:23015756 and PMID:23045692)\",\n      \"pmids\": [\"23015756\", \"23045692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MITD1 dimerizes through its C-terminal domain (identified as a phospholipase D-like domain by crystal structure), and this dimerization is important for MITD1 function.\",\n      \"method\": \"X-ray crystallography of MITD1 revealing a PLD-like dimer, corroborated by biochemical dimerization assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with biochemical validation in one rigorous study; dimerization through C-terminal domain also noted in the parallel paper\",\n      \"pmids\": [\"23045692\", \"23015756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The C-terminal PLD-like domain of MITD1 binds membranes, as revealed by the crystal structure and membrane-binding assays.\",\n      \"method\": \"Crystal structure determination plus membrane-binding assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure plus direct membrane-binding assay in a single rigorous paper\",\n      \"pmids\": [\"23045692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MITD1 negatively regulates the interaction between IST1 and VPS4; because IST1 binding modulates VPS4 ATPase activity, MITD1 may function through downstream effects on VPS4-mediated ESCRT filament remodeling during abscission.\",\n      \"method\": \"Binding competition assays (Co-IP/pulldown) showing MITD1 reduces IST1-VPS4 interaction\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — defined competitive binding experiment in a single lab, single method for the VPS4-regulation part\",\n      \"pmids\": [\"23015756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ANKRD35 destabilizes MITD1 protein by binding SUMO2, and RBCK1 (an E3 ubiquitin ligase) promotes ANKRD35 degradation, thereby stabilizing MITD1; the RBCK1-ANKRD35-MITD1-ANXA1 axis regulates AKT and ERK phosphorylation in ccRCC cells.\",\n      \"method\": \"In vitro and in vivo studies including knockdown/overexpression with signaling readouts (AKT/ERK phosphorylation), protein interaction assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — mechanistic pathway placement with signaling readouts, single lab, multiple methods but not fully reconstituted\",\n      \"pmids\": [\"36732658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MITD1 knockdown in ccRCC cells induces ferroptosis and suppresses tumor growth and migration through the TAZ/SLC7A11 pathway; TAZ overexpression rescues the ferroptotic phenotype caused by MITD1 loss.\",\n      \"method\": \"siRNA knockdown with ferroptosis assays, TAZ overexpression rescue experiments, Western blot for SLC7A11\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — epistasis (rescue experiment) plus defined pathway placement, single lab\",\n      \"pmids\": [\"36046690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MITD1 inhibits flavivirus (WNV, USUV, Zika, dengue) RNA replication by sequestering specific ESCRT-III proteins required for the formation of viral replication factories; MITD1 is an interferon-stimulated gene selectively induced in brain cells (microglia) and is an essential mediator of IFN-I anti-flavivirus activity in human microglial-like cells.\",\n      \"method\": \"Arrayed ISG expression screen, viral replication assays, ESCRT-III interaction studies, IFN-I treatment of microglial-like cells with MITD1 knockdown\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional screen followed by mechanistic validation (ESCRT-III sequestration, cell-type-specific IFN pathway), single lab with multiple orthogonal methods\",\n      \"pmids\": [\"40112111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"FOXO4 binds the MITD1 promoter (identified by ChIP-seq) and transcriptionally upregulates MITD1; MITD1 acts downstream of FOXO4 to protect trophoblast cells from ferroptosis (lipid peroxidation), and FOXO4 knockdown reduces MITD1 levels while overexpression restores them.\",\n      \"method\": \"ChIP-seq for FOXO4 promoter binding, gain- and loss-of-function experiments with ferroptosis readouts (lipid peroxidation, cell viability)\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP-seq plus functional rescue, single lab, mechanistic link established but not fully reconstituted\",\n      \"pmids\": [\"42201761\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MITD1 is an ESCRT-III–interacting protein (binding CHMP1B, CHMP2A, and IST1 via its MIT domain) that is recruited to the midbody to facilitate abscission during cytokinesis; its C-terminal phospholipase D-like domain mediates membrane binding and homodimerization, and it negatively regulates IST1–VPS4 interaction to modulate ESCRT filament remodeling. Beyond cytokinesis, MITD1 sequesters ESCRT-III subunits to block flavivirus replication-factory formation as a brain-enriched interferon-stimulated antiviral factor, is transcriptionally controlled by FOXO4 to suppress ferroptosis in trophoblasts via the TAZ/SLC7A11 axis, and is stabilized by the RBCK1–ANKRD35–SUMO2 ubiquitin pathway to regulate AKT/ERK signaling in renal carcinoma cells.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MITD1 is an ESCRT-III–interacting protein that functions in the abscission phase of cytokinesis, where its N-terminal MIT domain directly binds the ESCRT-III subunits CHMP1B, CHMP2A, and IST1 to drive recruitment to the midbody [#0], and its loss destabilizes the midbody and causes abscission failure [#1]. Its C-terminal phospholipase D-like domain mediates both homodimerization and direct membrane binding, properties resolved by crystallography that are important for MITD1 function [#2, #3]. Mechanistically, MITD1 negatively regulates the IST1–VPS4 interaction, positioning it as a modulator of VPS4-driven ESCRT filament remodeling during abscission [#4]. Beyond cytokinesis, MITD1 is an interferon-stimulated gene selectively induced in microglia that restricts flavivirus replication by sequestering ESCRT-III subunits required for viral replication-factory formation, and is essential for type I interferon anti-flavivirus activity in human microglial-like cells [#7]. In renal carcinoma cells, MITD1 is stabilized through an RBCK1–ANKRD35–SUMO2 ubiquitin axis and influences AKT and ERK phosphorylation [#5], while its depletion induces ferroptosis via the TAZ/SLC7A11 pathway [#6]; in trophoblasts MITD1 is a transcriptional target of FOXO4 that protects against ferroptotic lipid peroxidation [#8].\",\n  \"teleology\": [\n    {\n      \"year\": 2012,\n      \"claim\": \"Established that MITD1 is a bona fide ESCRT-III interactor recruited to the midbody, answering how an uncharacterized MIT-domain protein engages the cytokinetic machinery.\",\n      \"evidence\": \"Reciprocal Co-IP/pulldown binding assays with CHMP1B, CHMP2A, IST1 plus midbody localization microscopy, replicated in two concurrent papers\",\n      \"pmids\": [\"23015756\", \"23045692\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative affinity and stoichiometry of the three ESCRT-III interactions not resolved\", \"Structural basis of MIT-domain recognition not defined here\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated a functional cytokinesis role by showing depletion causes abscission failure, moving MITD1 from a binding partner to a required effector.\",\n      \"evidence\": \"siRNA knockdown with midbody imaging and abscission phenotype readout, reproduced in two papers\",\n      \"pmids\": [\"23015756\", \"23045692\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise step within abscission that MITD1 controls not pinpointed\", \"Whether the phenotype depends on membrane binding vs ESCRT recruitment not separated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined the C-terminal domain architecture, revealing a PLD-like fold that mediates dimerization and membrane binding, explaining how MITD1 couples to membranes.\",\n      \"evidence\": \"X-ray crystallography of the MITD1 PLD-like dimer plus biochemical dimerization and membrane-binding assays\",\n      \"pmids\": [\"23045692\", \"23015756\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lipid specificity of membrane binding not characterized\", \"Whether the PLD-like domain retains catalytic activity not addressed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Proposed a regulatory mechanism in which MITD1 tunes ESCRT remodeling by antagonizing the IST1–VPS4 interaction.\",\n      \"evidence\": \"Binding competition Co-IP/pulldown assays showing MITD1 reduces IST1-VPS4 interaction\",\n      \"pmids\": [\"23015756\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single method/single lab for the VPS4-regulation claim\", \"Direct consequence on VPS4 ATPase activity in cells not measured\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked MITD1 to ferroptosis control in cancer, showing its loss triggers ferroptotic death via a defined signaling axis.\",\n      \"evidence\": \"siRNA knockdown with ferroptosis assays and TAZ-overexpression rescue, SLC7A11 Western blot in ccRCC cells\",\n      \"pmids\": [\"36046690\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"How a cytokinetic ESCRT protein mechanistically connects to TAZ/SLC7A11 not resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Placed MITD1 within a ubiquitin/SUMO stabilization network governing its protein levels and downstream AKT/ERK signaling in renal carcinoma.\",\n      \"evidence\": \"Knockdown/overexpression with AKT/ERK phosphorylation readouts and protein interaction assays in ccRCC, in vitro and in vivo\",\n      \"pmids\": [\"36732658\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pathway not fully reconstituted in vitro\", \"Direct mechanism linking MITD1-ANXA1 to AKT/ERK not detailed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealed an antiviral role, establishing MITD1 as a brain-enriched interferon-stimulated gene that blocks flavivirus replication by sequestering ESCRT-III.\",\n      \"evidence\": \"Arrayed ISG screen, viral replication assays, ESCRT-III interaction studies, and IFN-I treatment with MITD1 knockdown in microglial-like cells\",\n      \"pmids\": [\"40112111\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Which specific ESCRT-III subunits are rate-limiting for sequestration not fully defined\", \"In vivo relevance of microglial restriction not established\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Identified upstream transcriptional control of MITD1 by FOXO4 in a ferroptosis-protective context in trophoblasts.\",\n      \"evidence\": \"FOXO4 ChIP-seq promoter binding plus gain/loss-of-function with lipid peroxidation and viability readouts\",\n      \"pmids\": [\"42201761\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab and not fully reconstituted\", \"Molecular mechanism by which MITD1 suppresses lipid peroxidation not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the conserved ESCRT-III/membrane-binding biochemistry of MITD1 mechanistically connects to its disparate ferroptosis, signaling, and antiviral roles remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying mechanism linking cytokinetic ESCRT function to ferroptosis/AKT-ERK regulation\", \"Cell-type specificity of the antiviral vs proliferative roles not reconciled\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CHMP1B\", \"CHMP2A\", \"IST1\", \"VPS4\", \"ANKRD35\", \"RBCK1\", \"FOXO4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}